Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PPID | Q08752 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19331999 | 0.88 | NPY5R (0.48) | PPIDSMN1; SMN2NPY5RHPGDRAB9A | |
| SCHEMBL13714950 | 0.86 | NPY5R (0.44) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL491489 | 0.85 | RXFP1 (0.47) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL3024941 | 0.84 | ENPP2 (0.46) | KMT2AMEN1MAPTSMN1; SMN2NPY5R | |
| SCHEMBL5277253 | 0.84 | NPY5R (0.43) | MAPTNPY5RALDH1A1SRC | |
| SCHEMBL5280572 | 0.82 | ENPP2 (0.45) | MAPTTSHRNPY5RHPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL3024939 | 0.82 | ENPP2 (0.45) | KMT2AMEN1MAPTSMN1; SMN2NPY5R | |
| SCHEMBL491746 | 0.82 | BTK (0.57) | LMNANPY5R | |
| SCHEMBL3014822 | 0.81 | ENPP2 (0.50) | NPY5R | |
| SCHEMBL13003196 | 0.81 | CYP17A1 (0.51) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362226-A1 | Diagnostic method for neurodegenerative diseases based on measurement of SIRT1 levels or activity | The President and Fellows of Harvard College (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2289504-A2 | SIRT1 modulators for manipulating cell/organism lifespan/stress response | President and Fellows of Harvard College (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2236131-A2 | Compositions for manipulating the lifespan and stress response of cells and organisms | President and Fellows of Harvard College (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20100035885-A1 | COMPOSITIONS FOR MANIPULATING THE LIFESPAN AND STRESS RESPONSE OF CELLS AND ORGANISMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-02-11 | — | — | US | disclosed |
| US-7544497-B2 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1863461-A2 | SIRTUIN RELATED THERAPEUTICS AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES | The President and Fellows of Harvard College (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1850840-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | Sirtris Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1841415-A2 | USE OF SIRTUIN-ACTIVATING COMPOUNDS FOR TREATING FLUSHING AND DRUG INDUCED WEIGHT GAIN | Sirtris Pharmaceuticals, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060276416-A1 | Methods and compositions for treating flushing and drug induced weight gain | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006096780-A2 | SIRTUIN RELATED THERAPEUTICS AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006079021-A2 | USE OF SIRTUIN-ACTIVATING COMPOUNDS FOR TREATING FLUSHING AND DRUG INDUCED WEIGHT GAIN | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006076681-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1648437-A2 | SIRT1 MODULATORS FOR MANIPULATING CELL/ORGANISM LIFESPAN/STRESS RESPONSE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20060084135-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | BIOMOL INTERNATIONAL, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060025337-A1 | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-02-02 | — | — | US | disclosed |
| US-20050136537-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-06-23 | — | — | US | disclosed |
| US-20050096256-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005002672-A2 | SIRT1 MODULATORS FOR MANIPULATING CELLS/ORGANISM LIFESPAN/STRESS RESPONSE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005002555-A2 | SIRT1 MODULATORS FOR MANIPULATING CELL/ORGANISM LIFESPAN/STRESS RESPONSE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035885-A1 | COMPOSITIONS FOR MANIPULATING THE LIFESPAN AND STRESS RESPONSE OF CELLS AND ORGANISMS | SIRT1, SIRT2, FOXO3 | KMT2A 4334/4885MEN1 1594/4885TDP1 281/4885 |
| US-20060025337-A1 | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases | SIRT1, SIRT2, SIRT3 | KMT2A 3681/4885MEN1 2563/4885TDP1 319/4885 |
| US-20060276416-A1 | Methods and compositions for treating flushing and drug induced weight gain | SIRT2, SIRT1, SIRT7 | KMT2A 153/4885MEN1 2086/4885TDP1 4563/4885 |
| US-20050096256-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | SIRT1, SIRT2, FOXO3 | KMT2A 4334/4885MEN1 1594/4885TDP1 281/4885 |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRT2, SIRT1, SIRT3 | KMT2A 1489/4885MEN1 739/4885TDP1 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.